

# Se-Hoon Lee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6806906/publications.pdf>

Version: 2024-02-01

152  
papers

9,005  
citations

38742

50  
h-index

48315

88  
g-index

153  
all docs

153  
docs citations

153  
times ranked

13058  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4138-4148.	1.6	614
2	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology</i> , The, 2009, 10, 757-763.	10.7	571
3	The transcriptional landscape and mutational profile of lung adenocarcinoma. <i>Genome Research</i> , 2012, 22, 2109-2119.	5.5	524
4	An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1279-1285.	0.8	268
5	DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. <i>Nature Communications</i> , 2019, 10, 4278.	12.8	263
6	Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of <i>ERBB2</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14476-14481.	7.1	246
7	Mechanisms of Acquired Resistance to AZD9291. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1736-1744.	1.1	202
8	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. <i>Breast Cancer Research</i> , 2011, 13, R22.	5.0	187
9	Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1474-1480.	1.1	148
10	Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Radiation Therapy and Concomitant Temozolomide: Comparison Study of Standard and High- <i>b</i> -Value Diffusion-weighted Imaging. <i>Radiology</i> , 2013, 269, 831-840.	7.3	147
11	Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 415-422.	1.1	147
12	Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 758-765.	1.4	144
13	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. <i>Nature Communications</i> , 2017, 8, 1377.	12.8	137
14	Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. <i>Cancer</i> , 2013, 119, 1195-1202.	4.1	136
15	Palliative chemotherapy for pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2007, 58, 112-115.	2.0	132
16	Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. <i>BMC Cancer</i> , 2007, 7, 203.	2.6	126
17	Sunitinib in metastatic renal cell carcinoma patients with brain metastases. <i>Cancer</i> , 2011, 117, 501-509.	4.1	126
18	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. <i>Lung Cancer</i> , 2009, 65, 80-84.	2.0	118

#	ARTICLE	IF	CITATIONS
19	Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2012, 77, 288-292.	2.0	115
20	Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1069-1074.	1.1	110
21	Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 193-202.	1.1	104
22	Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy: Differentiation of True Progression from Pseudoprogression with Quantitative Dynamic Contrast-enhanced MR Imaging. <i>Radiology</i> , 2015, 274, 830-840.	7.3	102
23	Diffusion-weighted MR Imaging for the Differentiation of True Progression from Pseudoprogression Following Concomitant Radiotherapy with Temozolomide in Patients with Newly Diagnosed High-grade Gliomas. <i>Academic Radiology</i> , 2012, 19, 1353-1361.	2.5	96
24	Aggressiveness of Cancer-Care near the End-of-Life in Korea. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 381-386.	1.3	94
25	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928.	1.6	94
26	Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment. <i>Lung Cancer</i> , 2008, 61, 30-34.	2.0	89
27	An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012, 48, 324-332.	2.8	84
28	Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1252-1259.	4.1	84
29	L-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms. <i>International Journal of Biochemistry and Cell Biology</i> , 2004, 36, 2180-2195.	2.8	82
30	Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. <i>Lung Cancer</i> , 2012, 77, 460-463.	2.0	82
31	The role of PET/CT in detection of gastric cancer recurrence. <i>BMC Cancer</i> , 2009, 9, 73.	2.6	81
32	ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 60, 401-407.	2.0	78
33	Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 446-454.	6.4	75
34	Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4383-4388.	7.0	74
35	Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. <i>International Journal of Cancer</i> , 2009, 124, 1457-1462.	5.1	69
36	CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. <i>Tumor Biology</i> , 2012, 33, 121-129.	1.8	68

#	ARTICLE	IF	CITATIONS
37	Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea. <i>Journal of Korean Medical Science</i> , 2014, 29, 980.	2.5	67
38	Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors. <i>Journal of Thoracic Oncology</i> , 2011, 6, 905-912.	1.1	66
39	Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. <i>Lung Cancer</i> , 2012, 77, 572-577.	2.0	66
40	Clinicopathologic Analysis of ROS1-Rearranged Non-Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1445-1450.	1.1	65
41	Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. <i>BMC Cancer</i> , 2008, 8, 148.	2.6	64
42	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. <i>Journal of Neuro-Oncology</i> , 2012, 106, 303-313.	2.9	64
43	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. <i>BMC Cancer</i> , 2007, 7, 63.	2.6	63
44	Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 51-61.	2.8	63
45	Tumor Burden is Predictive of Survival in Patients With Non-Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib. <i>Clinical Lung Cancer</i> , 2013, 14, 383-389.	2.6	63
46	Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer. <i>Journal of Pathology</i> , 2017, 243, 307-319.	4.5	63
47	Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1758-1766.	1.1	60
48	Synthetic lethality-mediated precision oncology via the tumor transcriptome. <i>Cell</i> , 2021, 184, 2487-2502.e13.	28.9	60
49	MDSC subtypes and CD39 expression on CD8 <sup>+</sup> T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. <i>European Journal of Immunology</i> , 2020, 50, 1810-1819.	2.9	57
50	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 313-319.	1.5	54
51	Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 320-325.	1.1	54
52	Regulatory (FoxP3+) T cells and TGF- $\beta$ 2 predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 18994.	3.3	52
53	Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. <i>BMC Cancer</i> , 2008, 8, 374.	2.6	51
54	Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. <i>Neuro-Oncology</i> , 2011, 13, 195-202.	1.2	51

#	ARTICLE	IF	CITATIONS
55	Analysis of the BRAFV600E Mutation in Central Nervous System Tumors. <i>Translational Oncology</i> , 2012, 5, 430-436.	3.7	51
56	Expression level of <i>hTERT</i> is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. <i>Oncotarget</i> , 2014, 5, 3399-3407.	1.8	50
57	Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 3579-3586.	4.1	49
58	Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute. <i>Cancer Research and Treatment</i> , 2015, 47, 555-563.	3.0	49
59	First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective analysis of clinical predictors. <i>Cancer Science</i> , 2010, 101, 1199-1203.	3.9	48
60	Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles. <i>Oncology</i> , 2011, 80, 395-405.	1.9	48
61	Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, e147-e150.	1.6	47
62	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. <i>PLoS ONE</i> , 2018, 13, e0189766.	2.5	46
63	A Phase III Randomized Trial of Combined Chemoradiotherapy Versus Radiotherapy Alone in Locally Advanced Non-Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 238-243.	1.3	45
64	The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas. <i>Translational Oncology</i> , 2012, 5, 393-401.	3.7	43
65	Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. <i>BMC Cancer</i> , 2010, 10, 448.	2.6	42
66	Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 351-358.	3.4	42
67	Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 477-480.	1.3	41
68	Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 153-160.	2.5	41
69	Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 10-14.	2.3	40
70	Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 237-245.	1.1	40
71	High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Non-Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy. <i>Clinical Cancer Research</i> , 2006, 12, 4232-4236.	7.0	38
72	A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. <i>Lung Cancer</i> , 2011, 71, 65-69.	2.0	38

#	ARTICLE	IF	CITATIONS
73	Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 570-578.	1.7	38
74	Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 134, 7-15.	2.0	38
75	Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. <i>Neuropathology</i> , 2009, 29, 443-449.	1.2	37
76	Clinical dissection of multicentric Castleman disease. <i>Leukemia and Lymphoma</i> , 2011, 52, 1517-1522.	1.3	36
77	Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 122-128.	2.0	35
78	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2006, 54, 201-207.	2.0	35
79	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. <i>Nature Communications</i> , 2020, 11, 951.	12.8	34
80	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1301-1308.	2.5	32
81	Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 40.	1.7	31
82	Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. <i>Head and Neck</i> , 2009, 31, 1121-1128.	2.0	30
83	Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2009, 65, 204-207.	2.0	29
84	Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. <i>Journal of Neuro-Oncology</i> , 2011, 103, 595-602.	2.9	29
85	Phase II Study of the Safety and Efficacy of Temsirolimus in East Asian Patients with Advanced Renal Cell Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 836-844.	1.3	28
86	Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. <i>Supportive Care in Cancer</i> , 2012, 20, 395-403.	2.2	28
87	Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1189-1194.	1.1	26
88	Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. <i>Cancer Research and Treatment</i> , 2017, 49, 193-203.	3.0	26
89	Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. <i>International Journal of Cancer</i> , 2019, 145, 2433-2439.	5.1	26
90	Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M mutant non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 2704-2712.	4.1	26

#	ARTICLE	IF	CITATIONS
91	Definitive Radiotherapy With or Without Chemotherapy for T3-4N0 Squamous Cell Carcinoma of the Maxillary Sinus and Nasal Cavity. Japanese Journal of Clinical Oncology, 2010, 40, 542-548.	1.3	25
92	Clinical Course of Neuroendocrine Tumors With Different Origins (the Pancreas, Gastrointestinal) Tj ETQq0 0 0 rgBT J/Overlock_10 Tf 50	1.3	25
93	EGFR mutations as a predictive marker of cytotoxic chemotherapy. Lung Cancer, 2012, 77, 433-437.	2.0	25
94	Activation of Raf1 and the ERK pathway in response to l-ascorbic acid in acute myeloid leukemia cells. Cellular Signalling, 2005, 17, 111-119.	3.6	24
95	Pulmonary resection in patients with nonsmallâ€cell lung cancer treated with gammaâ€knife radiosurgery for synchronous brain metastases. Cancer, 2008, 112, 1780-1786.	4.1	24
96	Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. Respiratory Medicine, 2020, 161, 105853.	2.9	23
97	Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. BMC Cancer, 2009, 9, 450.	2.6	22
98	Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors. Journal of Korean Medical Science, 2014, 29, 1094.	2.5	22
99	The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2013, 112, 277-283.	2.9	21
100	A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. Oncologist, 2019, 24, 751-e231.	3.7	21
101	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Cancer Research and Treatment, 2014, 46, 323-330.	3.0	21
102	A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers. Lung Cancer, 2003, 42, 227-235.	2.0	20
103	Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients. Lung Cancer, 2008, 62, 381-384.	2.0	20
104	Influence of chemotherapy on nitric oxide synthase, indoleâ€amineâ€2,3â€dioxygenase and CD124 expression in granulocytes and monocytes of nonâ€small cell lung cancer. Cancer Science, 2012, 103, 155-160.	3.9	20
105	A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. Oncologist, 2015, 20, 1119-1120.	3.7	20
106	<i><sc>IDH2</sc></i> mutation in gliomas including novel mutation. Neuropathology, 2015, 35, 236-244.	1.2	19
107	CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation. Leukemia and Lymphoma, 2006, 47, 1253-1259.	1.3	18
108	Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. Supportive Care in Cancer, 2007, 15, 631-636.	2.2	18

#	ARTICLE	IF	CITATIONS
109	Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging. <i>Journal of Neuro-Oncology</i> , 2013, 112, 427-435.	2.9	18
110	Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients. <i>Cancer Research and Treatment</i> , 2012, 44, 242-250.	3.0	17
111	Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data. <i>Journal of Breast Cancer</i> , 2012, 15, 427.	1.9	15
112	Prognosis Prediction of Measurable Enhancing Lesion after Completion of Standard Concomitant Chemoradiotherapy and Adjuvant Temozolomide in Glioblastoma Patients: Application of Dynamic Susceptibility Contrast Perfusion and Diffusion-Weighted Imaging. <i>PLoS ONE</i> , 2014, 9, e113587.	2.5	15
113	Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 408-412.	3.0	15
114	A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. <i>BMC Urology</i> , 2016, 16, 46.	1.4	14
115	Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. <i>Head and Neck</i> , 2016, 38, 277-284.	2.0	14
116	Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 65, 242-246.	2.0	13
117	Integrin $\alpha 3$ Inhibition Enhances the Antitumor Activity of ALK Inhibitor in <i>ALK</i> -Rearranged NSCLC. <i>Clinical Cancer Research</i> , 2018, 24, 4162-4174.	7.0	13
118	Comparison of Treatment Outcomes Between Involved-field and Elective Nodal Irradiation in Limited-stage Small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 948-954.	1.3	12
119	Clinical Usefulness of AJCC Response Criteria for Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 2242-2249.	1.5	12
120	Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. <i>Scientific Reports</i> , 2020, 10, 13231.	3.3	11
121	EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 548-554.	1.3	10
122	Primary Intracranial Germ Cell Tumor Originating From Septum Pellucidum That Mimics Central Neurocytoma. <i>Journal of Clinical Oncology</i> , 2012, 30, e274-e277.	1.6	10
123	Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2018, 122, 160-164.	2.0	10
124	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 891-898.	1.7	10
125	Clinical significance of tumor-infiltrating FOXP3+ T cells in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. <i>Cancer Science</i> , 2011, 102, 1972-1976.	3.9	9
126	Role of Chemotherapy on Brain Metastasis. <i>Progress in Neurological Surgery</i> , 2012, 25, 110-114.	1.3	9



#	ARTICLE	IF	CITATIONS
127	Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. <i>PLoS Medicine</i> , 2020, 17, e1003091.	8.4	9
128	Application of Cancer Genomics to Solve Unmet Clinical Needs. <i>Genomics and Informatics</i> , 2013, 11, 174.	0.8	9
129	The Lack of CD34 Expression in Gastrointestinal Stromal Tumors is Related to Cystic Degeneration Following Imatinib Use. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 1020-1027.	1.3	8
130	Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers. <i>Journal of Korean Medical Science</i> , 2017, 32, 415.	2.5	8
131	Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1605-1617.	4.2	8
132	Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. <i>Journal of Korean Neurosurgical Society</i> , 2021, 64, 271-281.	1.2	8
133	Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. <i>Medical Oncology</i> , 2008, 25, 447-450.	2.5	7
134	The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 68, 427-432.	2.0	7
135	Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. <i>PLoS ONE</i> , 2015, 10, e0133371.	2.5	7
136	Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. , 2020, 8, e001199.		7
137	Influential Factors for the Collection of Peripheral Blood Stem Cells and Engraftment in Acute Myeloid Leukemia Patients in First Complete Remission. <i>International Journal of Hematology</i> , 2005, 81, 258-263.	1.6	6
138	Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin as First-line Therapy for Advanced Colorectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 214-217.	1.3	6
139	Junction Location Identifier (JuLI). <i>Journal of Molecular Diagnostics</i> , 2020, 22, 304-318.	2.8	6
140	Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer. <i>Cancer Research and Treatment</i> , 2012, 44, 227-234.	3.0	6
141	Increasing Nodal Ratio is a Poor Prognostic Factor for Survival in Stage III-IV (M0) Gastric Cancer Patients Who Received Curative Surgery Followed by Adjuvant Chemotherapy: A Retrospective Study. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 245-252.	1.3	5
142	Benefit of Targeted DNA Sequencing in Advanced Non-EGFR Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. <i>Clinical Lung Cancer</i> , 2020, 21, e182-e190.	2.6	5
143	VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 143-147.	2.1	4
144	Early Concurrent Chemoradiotherapy with Prolonged Oral Etoposide and Cisplatin for Limited-stage Small-cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 620-625.	1.3	3

#	ARTICLE	IF	CITATIONS
145	The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 182-188.	3.0	3
146	Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach. <i>Cancers</i> , 2021, 13, 6050.	3.7	3
147	Preradiation Chemotherapy with ACNU-CDDP in Patients with Newly Diagnosed Glioblastoma: A Retrospective Analysis. <i>Chemotherapy</i> , 2009, 55, 145-154.	1.6	2
148	Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 541.	2.9	1
149	Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC. <i>Lancet Respiratory Medicine</i> , 2017, 5, e10.	10.7	0
150	The Role of Chemotherapy in Anaplastic Astrocytoma Patients. <i>Journal of Korean Neurosurgical Society</i> , 2012, 51, 199.	1.2	0
151	Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategies. <i>EPMA Journal</i> , 2021, 12, 629-645.	6.1	0
152	Gene essentiality for tumour growth influences neoantigen-directed immunoediting. <i>Clinical and Translational Medicine</i> , 2022, 12, e714.	4.0	0